Compare Immunovant Inc. Common Stock (IMVT) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs AT&T Inc. — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while AT&T Inc. trades at $23.18 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 27.3× Immunovant Inc. Common Stock's market cap, and AT&T Inc. pays a 4.46% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| IMVT | T | |
|---|---|---|
Market Cap | $6.25B | $170.42B |
Volume | 1,755,411 | 50,780,036 |
Sector | Health | Media |
52-Week High | $44.96 | $29.10 |
52-Week Low | $17.03 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $5.35B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AT&T (T) trades at $24.475, up 0.2% on the day, with a bearish technical signal but strong fundamentals including a low P/E of 8.08 and robust profitability. Recent earnings have consistently beaten estimates, and the company maintains a solid dividend. Cash flow improved significantly in 2025 to $15.12B net, while debt levels remain manageable. News highlights a $3B fiber deal with Corning and joint ventures to expand coverage.
The stock appears undervalued with a consensus price target of $27.61, offering a 13% upside. Key opportunities include fiber expansion and wireless growth, but risks involve intense competition, high debt, and potential dividend sustainability concerns. Analyst sentiment is mixed with 44% buy ratings, suggesting cautious optimism for long-term income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
